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osting by EAbstract The efﬁcacy of synthetic gonadotrophin-releasing hormone (GnRH) analogue in
improving the folliculogenesis of ducks has not been established. The aim of the study was to inves-
tigate the effect of oral administration of GnRH analogue as luteinizing hormone releasing hor-
mone A2 (LHRH-A2) on expression of relevant genes, egg production, changes of hormone
levels and an ovarian follicle development in ducks. Five hundred ducks at 220 days old were ran-
domly allotted to ﬁve groups, where each bird received daily in food 0, 5, 10, 15, or 20 lg LHRH-A2
for 60 days. In all treated groups, a non-signiﬁcant increase in the level of GnRH receptor was
noticed as compared to the corresponding control. Interestingly, the egg product in the 10 and
15 lg LHRH-A2 groups was profoundly increased (P< 0.05) if compared to 0 and 5 lg LHRH-
A2 groups or control. A reduction in circulating prolactin (PRL) levels occurs concurrently with
an increase in progesterone (P4) and estradiol (E2) particularly in 5, 10 and 15 lg LHRH-A2 groups.
Maximal apoptotic percentage for the granulosa cells was obtained in 20 lg LHRH-A2 group as
compared to control or 5, 10 and 15 lg treatment groups. Finally, these data suggest that the oral
administration of 10 and 15 lg LHRH-A2 may induce ovarian cycle and play vital gonadotropeaud University, College of
kzoheir@ksu.edu.sa (K.M.A.
Ahmed).
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94 K.M.A. Zoheir, R.G. Ahmedrole during the folliculogenesis process in ducks. This study also demonstrated a need to concen-
trate further research on the potential effect of GnRH during the early period to improve the repro-
ductive performance.
ª 2012 Academy of Scientific Research & Technology. Production and hosting by Elsevier B.V.
All rights reserved.1. Introduction
The natural gonadotropin-releasing hormone (GnRH) is a
deca-peptide produced by specialized neurons in the basal
hypothalamus and released to the pituitary via a portal circu-
latory system [10,61]. Its ability to stimulate luteinizing hor-
mone (LH) and follicle stimulating hormone (FSH) release
has been utilized for various veterinary purposes, including
regulation of ovarian function and optimization of timed
insemination in controlled breeding programs [62], induction
of ovulation in the post-partum period [44], and treatment of
ovarian follicular cysts in cattle [36]. Also, it is well known that
GnRH is involved in the regulation of ovarian development in
mammals through paracrine/autocrine pathways [37,50,53].
GnRHs have been isolated and sequenced from vertebrate spe-
cies [66] (Wierman, 1996) across the phylogenetic scale includ-
ing tunicates, primitive protochordates [47]. In several species,
more than one form of GnRH exists [47].
Because the GnRH family plays an important role in nor-
mal reproduction, interest has centered on developing more
potent GnRH analogues (both agonists and subsequently
antagonists) to intervene in some diseases of the reproductive
system. The birds’ embryos can be used as a model for inves-
tigating toxicity of different compounds such as estrogenic
compounds because they are prove to be easy to access
[4,16]. Authors have been described how to investigate the ef-
fect of environmental or synthetic estrogenic compounds using
direct injection into eggs in the early stages of incubation
[4,16]. Two types of GnRH, GnRH-I and GnRH-II are se-
creted from avian hypothalamus. GnRH-I plays a critical role
in the reproduction in birds [35]. Furthermore, GnRH is re-
quired for a normal reproduction in vertebrates, and released
in pastille fashion from neurosecretory cells in the hypothala-
mus [72]. During assisted reproductive technology protocols,
GnRH agonists are often used to deliver pulsatile release of
GnRH, which in turn, increases the release of FSH and LH
in cases of hypogonadotropic hypogonadism [54]. It has sug-
gested that the use of GnRH agonists for the control of repro-
duction is of growing interest to increase the efﬁciency of
reproductive performances in farm animals [25,41]. The use
of GnRH and its analogue has been investigated in cows
[59,61], mare [21], sheep and goats [26], ﬁsh [68], dogs [8], wild-
life [2,5,42,54] and poultry [37,48]. Although parenteral admin-
istration of GnRH agonists practiced in ﬂocks is difﬁcult,
GnRH agonists were primarily used by parenteral administra-
tion as discussed by [26,48]. Interestingly, GnRH family plays
an important role in normal reproduction, so it has centered
on developing more potent GnRH analogues (both agonists
and subsequently antagonists) to intervene in some diseases
of the reproductive system [25].
However, studies on GnRH-I expression are largely con-
ﬁned to the hypothalamus, with none on avian ovary.
Although the prepubertal changes of hypothalamic GnRH-I
have been documented in birds [12], nothing is known aboutthe pattern of ovarian expression of GnRH-I during this per-
iod of posthatch development. Thus, the objectives of this
study were to understand the effect of oral administration of
Gonadotropin-releasing hormone (GnRH) analogue as
Luteinizing Hormone Releasing Hormone A2 (LHRH-A2)
on expression of relevant genes, changes of hormone levels,
egg production and ovarian follicle development in ducks.
2. Materials and methods
2.1. Animals and treatments
Five hundred Pekin ducks (Anas platyrhynchos) (one male for
every three females), which were hatched and held in same con-
ditions, were allotted to ﬁve treatment groups of 100 birds each.
The feeding procedure during the whole experiment followed
the feeding and housing standards set for this breed. Ducks
were given free access to water and food under the same photo-
period of 12 h, which consisted of natural illumination during
the daytime, plus supplementary illumination of 80 lux by ﬂuo-
rescent tubes at times after sunset and before sunrise. At age
220 days, ducks received 0, 5, 10, 15, or 20 lg of LHRH-A2 dai-
ly mixed with feed. Experiments continued for 60 days.
2.2. Egg production and egg quality
Eggs were collected daily and egg production was recorded.
Every treatment group contained ﬁve replicates and each rep-
licate contained 20 birds. Mean egg weight/replicate was deter-
mined by weighing all the eggs on three consecutive days every
week. The yolk, albumin, and shell percentages were deter-
mined using ﬁve eggs/pen at a biweekly interval.
2.3. Detection of granulosa cell apoptosis
At the end of the experiment, three ducks of each replicate
were sacriﬁced. The ovaries were immediately removed by cer-
vical dislocation, and kept in PBS solution. The granulosa lay-
ers were then collected from the follicle wall according to the
technique described by [20], and then the cells were dissociated
in collagenase containing medium PBS. Cells were stained with
Annexin V, a phospholipid binding protein that detects early
apoptosis, and with propidium iodide (PI), a membrane imper-
meable stain, to discriminate between dead and apoptotic cells.
Brieﬂy, the Annexin V incubation reagent was prepared by
mixing 10 lL of 10· binding buffer, 10 lL of PI, 1 lL of An-
nexin V-FITC, and 79 lL of distilled water. The cells were
gently re-suspended in the Annexin V incubation reagent in
the dark for 15 min at 18–24 C. Finally, 400 lL of 1· binding
buffer was added to each sample. After staining, cells were
analyzed by Flow Cytometry within 1 h for maximal signal.
Vital cells are negative for both PI and Annexin V, apoptotic
cells are Annexin V positive and PI negative, while necrotic
cells are positive for both PI and Annexin V.
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hormone level
Blood samples (were randomly selected from each replicate)
were taken from the brachial wing vein at 40 and 60 days at
8 h, after fasting for 18 h. Blood samples were allowed to clot,
then centrifuged at 3000 rpm for 15 min to collect blood ser-
um. An aliquot of serum was stored at 20 C until assayed
for progesterone (P4), prolactin (PRL) and estradiol (E2). E2,
P4 and PRL levels were assayed using the commercial RIA-test
kit. The assay sensitivity was less than 5 pg/ml for both E2 and
P4 and was less than 1.0 ng/mL for PRL. Coefﬁcients of vari-
ations between assays in E2 and P4 were less than 10%, and
within assay was less than 7% while were less than 6.0–
9.7%, and within assay was less than 2.2–5.4% for PRL.
2.5. RNA extraction
Total RNA was extracted from the hypothalamic tissue using
Trizol and the RNA concentration was then quantiﬁed by
measuring the absorbance at 260 nm in a photometer. Ratios
of absorption (260/280 nm) of all preparations were between
1.8 and 2.0. Aliquots of RNA samples were subjected to elec-
trophoresis through a 1.4% agarose–formaldehyde gel to ver-
ify their integrity.
2.6. Reverse transcription (RT) and polymerase chain reaction
(PCR)
Two micrograms of total RNA was reverse transcribed by
incubation at 42 C for 1 h in a 20 ll mixture consisting of
10 U avian myeloblastosis virus reverse transcriptase, 20 U
RNase inhibitor, 2.4 lM Oligo (dT10) primer, 1 mM each
dNTP, 50 mM Tris–HCl (pH 8.3), 10 mM MgCl2, 50 mM
KCl, 10 mM DDT, 0.5 mM spermidine. RNA samples were
denatured at 80 C for 5 min and placed on ice for 5 min to-
gether with the Oligo (dT10) primer and dNTP before reverse
transcription (RT). The RT reaction was terminated by heat-
ing at 95 C for 5 min and quickly cooled on ice. 2 lL of RT
reaction mix was used for PCR in a ﬁnal volume of 50 ll con-
taining 1 U Taq DNA polymerase, 5 mM Tris–HCl (pH 9.0),
10 mM NaCl, 0.1 mM DDT, 0.01 mM EDTA, 5% (w/v) glyc-
erol, 0.1% (w/v) Triton X-100, 0.2 mM each dNTP, 1.0–
2.0 mM MgCl2, 0.5 lM speciﬁc primers for respective target
genes. The PCR primers for GnRH, and b-actin were designed
according to [72]. The nucleotide sequences of these primers
and the PCR conditions set for respective genes were shown
in Table 1. Each target gene was co ampliﬁed with b-actin in
the same reaction. By adjusting the ratio of b-actin primers
to primers of the target genes in the reaction system, the over-







GnRH 202 bp F: 50-GCTTGGCTCAACACTGGTCT-30
R: 50-CTGGCTTCTCCTTCGATCAG-30
b-Actin 282 bp F: 50-ACGTCGCACTGGATTTCGAG-30
R: 50-TGTCAGCAATGCCAGGGTAC-30the level comparable to that of target genes. Different controls
were set to monitor the possible contaminations of genomic
and environment DNA both at the stage of RT and PCR.
All samples were included in the same run of RT-PCR and re-
peated three times. Both RT and PCR were performed in a
Gene Amp PCR System 9600.
2.7. Data analysis
Data are expressed as means ± standard error (SE), and were
evaluated for statistically signiﬁcant difference by one-way
analysis of variance (ANOVA) followed by Duncan multiple
comparison test, using Statistical Analysis System Package
for P-values <0.05 were considered signiﬁcant.
3. Results
3.1. Effect of gonadotropin-releasing hormone on mRNA
expression of GnRH
Data obtained about the expression of gonadotropin-releasing
hormone (GnRH) receptor of control and treated groups were
shown in Table 1. In all treated groups, the elevation in the
expression level was non-signiﬁcant (LSD; P> 0.05) when
compared to respective control values (1.00, 1.10, 1.15 and
1.15 ± 0.03 and 0.95 ± 0.04) (Fig. 1).
3.2. The production performance of ducks
It is clear from Table 2 that the egg production for each bird in
the 10 and 15 lg LHRH-A2 groups increased signiﬁcantly
(P< 0.05) compared to the 0 and 5 lg LHRH-A2 groups even
though this production was suppressed when the dose in-
creased to 20 lg. Furthermore, no difference in the egg weight,
egg shape index, egg shell thickness, albumen percentage, yolk
percentage and egg shell percentage was recorded between the
control and different treatment groups (Table 2).
3.3. The apoptosis of follicle granulosa cells
The results of apoptotic rate in different groups were repre-
sented in Table 3. The apoptotic percentage for granulosa cells
was enormously increased (P< 0.05) in 20 lg LHRH-A2 only
compared to 5, 10, and 15 lg treatments or control group.Figure 1 Histogram showing GnRH gene expression in ducks
hypothalamic tissue in each treatment group.
Table 3 The apoptosis of granulose cell in ducks follicles in each treatment group.
Treatments (lg/bird)
0 5 10 15 20
Apoptosis (%) 8.80 ± 2.60ab 5.89 ± 1.68b 5.95 ± 1.31b 5.49 ± 1.12b 13.03 ± 1.29a
Values within the same line with different superscripts are signiﬁcantly different at P< 0.05.
Table 4 Serum hormone parameters of ducks in each treatment group.
Treatments (lg/bird)
0 5 10 15 20
PRL (ng/mL) 0.33 ± 0.05a 0.18 ± 0.02b 0.12 ± 0.01c 0.10 ± 0.02c 0.30 ± 0.04a
P (ng/mL) 5.14 ± 0.26bc 6.31 ± 1.01ab 7.8 ± 1.02a 7.34 ± 0.95a 3.95 ± 1.45c
E2 (pg/mL) 199.59 ± 102.60b 275.96 ± 74.76ab 387.1 ± 2.1a 371.1 ± 42.4a 182.20 ± 87.03b
Values within the same line with different superscripts are signiﬁcantly different at P< 0.05.









Percentage of egg weight
Albumen Yolk Eggshell
5 0.33 ± 0.01b 150.0 ± 8.0 1.27 ± 0.1 0.54 ± 0.0 55.9 ± 1.6 35.20 ± 1.0 11.9 ± 0.3
10 0.38 ± 0.01a 142.0 ± 6.0 1.30 ± 0.0 0.51 ± 0.0 55.8 ± 1.8 36.2 ± 0.6 12.9 ± 1.2
15 0.38 ± 0.01a 148.7 ± 4.4 1.2 ± 0.05 0.55 ± 0.0 58.2 ± 1.56 33.9 ± 1.0 11.9 ± 0.7
20 0.25 ± 0.01c 145.7 ± 1.2 1.29 ± 0.0 0.56 ± 0.0 53.3 ± 1.39 34.2 ± 1.3 10.2 ± 0.5
Controls 0.31 ± 0.02b 144.5 ± 2.0 1.28 ± 0.0 0.6 ± 0.01 52.5 ± 1.7 32.7 ± 0.6 11.1 ± 1.0
Values within the same line with different superscripts are signiﬁcantly different at P< 0.05.
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As indicated in Table 4, the levels of progesterone (P4) and
estradiol (E2) increased signiﬁcantly (P< 0.05) in 5, 10 and
15 lg treatment groups as compared with the 20 lg treatment
group or corresponding control (Table 4). However, the oppo-
site direction was observed in the level of prolactin (PRL) (Ta-
ble 4).
4. Discussion
A gonadotropin-releasing hormone analogue (GnRH ana-
logue or analog), also known as a luteinizing hormone releas-
ing hormone agonist (LHRH agonist) or LHRH analogue is a
synthetic peptide drug modeled after the human hypothalamic
GnRH. A GnRH analogue is designed to interact with the
GnRH receptor and modify the release of pituitary gonadotro-
pins [follicle stimulating hormone (FSH) and luteinizing hor-
mone (LH)] for therapeutic purposes. A GnRH agonist is an
analogue that activates the GnRH receptor resulting in in-
creased secretion of FSH and LH. In the current study, a
non-signiﬁcant increase in the level of GnRH receptor was ob-
served in all treated groups if compared to the control. Simi-
larly, through radioligand binding assays, ligand-speciﬁc
binding sites for GnRH were demonstrated on granulosa
and luteal cells [22,45] and on Leydig cells [28,57]. These ﬁnd-
ings were further conﬁrmed in subsequent studies by other
researchers [27,65]. In situ hybridization studies revealed thelocalization of GnRH mRNA in granulosa cells of primary,
secondary, and tertiary follicles in the ovary [7,65]. Presence
of mRNA for GnRH receptors has also been identiﬁed in hu-
man granulosa luteal cells (hGLCs) using reverse transcription
polymerase chain reaction (RT-PCR) techniques [23,39]. In
addition, the presence of GnRH receptor mRNA expressions
was recorded in bovine ovary [49]. RT-PCR studies revealed
the presence of GnRH-R mRNA expression in both follicles
and corpus leteum (CL) tissues. On the other hand, Ni Y
et al. [38] have demonstrated the changes of GnRH-I, POMC
and NPY mRNA transcription in hypothalamus and IGF-I
and leptin levels in serum of Shaoxing ducks during puberty.
Their results have indicated that the down-regulation of
POMC and NPY genes in hypothalamus coincides with the
up-regulation of GnRH-I gene to initiate sexual maturation
in ducks. According to Ni et al. [38] who demonstrated that,
the developmental pattern of GnRH-I mRNA expression re-
ﬂects a slow maturational process of the GnRH neurons dur-
ing maturation in birds. However, the biosynthetic
mechanism(s) responsible for developmental changes in
GnRH-I mRNA levels is (are) currently unknown. In addition
and according to study of Zhao et al. [72] who concluded that
activation of hypothalamic expression of GnRH mRNA and
elevated level of serum E2 contribute to enhanced laying rate.
Taking the previous information, it can be concluded that the
GnRH receptor is expressed in the majority of gonadotropes
suggesting its role in the regulation of gonadotropin secretion.
This has led to the suggested hypothesis that GnRH has spe-
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ducks.
In the present study, in 10 and 15 lg luteinizing hormone
releasing hormone A2 (LHRH-A2) groups, the egg product
was increased signiﬁcantly (P< 0.05) compared to 0, 5 and
20 lg LHRH-A2 groups or control. However, the treatments
had little effect on the index of egg quality. Concomitantly
with this ﬁnding, the maximal apoptotic percentage for the
granulosa cells was observed in 20 lg LHRH-A2 group as
compared to control or 5, 10 and 15 lg LHRH-A2 groups.
Parenteral administration of GnRH agonists can stimulate
ovulation in many vertebrates [1,26,48] and increased the num-
ber of large preovulatory ovarian follicles [6]. It was clearly
that GnRH could induce ovulation of follicles that were phys-
iologically immature (<11 mm) [43,61]. In laying broiler bree-
der hens, increasing GnRH release can result in increased
plasma LH and decreased FSH, and, in turn, increase the
number of large preovulatory ovarian follicles [6]. Interest-
ingly, an uninterrupted subcutaneous administration of a
GnRH-agonist for 2 weeks also rapidly induced a normal es-
trus, with spontaneously occurring gonadotrophin surges and
fertile ovulation [8,9]. GnRH treatment appears to be effective
in stimulating a new ovulation/luteinisation of another follicle
as it would in a non-cystic cow [18,24]. On the other hand, the
apoptosis rate of granulosa cells was a predictor of the devel-
opmental potential of the corresponding oocytes [58]. In hu-
man luteinized granulosa cells, GnRH analogue triggered a
dose dependent increase in the incidence of apoptosis [24,58].
Moreover, Zhao et al. (2000) demonstrated that GnRH-A-in-
duced increased number of apoptotic bodies in human granu-
losa cells (obtained during oocyte retrieval for in vitro
fertilization). Whitelaw et al. [65] reported that during follicu-
lar phase, attretic follicle in rat showed a high mRNA expres-
sion for GnRH receptors. This variation with our experiment
might be attributed to numerous factors such as species, envi-
ronment, management, breed, animal age, breeding season,
individual farm effects, interval from calving to ﬁrst service,
reproductive/lactational status, and type of breeding. Gener-
ally, the current administration of LHRH-A2 can signiﬁcantly
inﬂuence apoptosis of follicle granulose cells of ducks where
the physiological doses of LHRH-A2 can inhibit granulosa cell
apoptosis of the follicle, and higher does could induce follicu-
lar granulosa cell apoptosis. These observations may be rein-
forced by several investigators [29,55,69,70]. Furthermore,
the inﬂuence of LHRH-A2 on ovary granulosa cells maybe
associated with the different pathways. There are two possible
channels by which LHRH-A2 may modulate the function of
the ovary. First, LHRH-A2 acts on GnRH receptors in the
pituitary to regulate the production and release of gonadotro-
pins FSH and LH from the anterior pituitary [60]. Secondly,
LHRH-A2 acts on the ovary directly. The direct effects of
GnRH and its agonist on the ovary have been supported by
the demonstration of speciﬁc, high-afﬁnity binding sites for
GnRH and its agonist [58,51]. It can be inferred from the
above mentioned results that LHRH-A2 (10 and 15 lg) is in-
volved in the regulation of follicular development, increase
egg production and decrease apoptotic rate in ducks.
Worth noting in the current study is that the concentrations
progesterone (P4) and estradiol (E2) were markedly increased
(P< 0.05) in 5, 10 and 15 lg LHRH-A2 groups as compared
to the 20 lg LHRH-A2 and control groups while the opposite
pattern was noticed in the level of prolactin (PRL). Similarly,Beck et al. [3] and Khan et al. [26] showed that treatment with
GnRH resulted in higher plasma progesterone concentrations.
In addition, GnRH can increase serum P4 concentrations in
the cow [19,67]. This increased progesterone could enhance
uterine function leading to increased conceptus growth/devel-
opment and production of the antiluteolytic embryonic protein
interferon-tau, which suppresses prostaglandin F2a release.
Moreover, it has been shown that high levels of progesterone
during the luteal phase delay the process of luteolysis
[26,30,40]. Foster et al. [14] and Howard et al. [19] reported
that the administration of GnRH on days 5 or 6 of the estrous
cycle overrides the negative feedback of progesterone on the
anterior pituitary, thereby allowing the secretion of both LH
and FSH, resulting in ovulation or luteinization of the follicle,
and subsequent formation of a corps leutum CL. Therefore,
the increase in CL number is likely responsible for the in-
creased progesterone concentrations in the GnRH group.
Also, studies on sheep [33] (McNatty and Land, 1979), mouse
[11], humans [32], porcine [63], chicken and domestic hen [52]
and turkey [46] suggest that low concentration of prolactin is
required for synthesis of progesterone, since high concentra-
tion of prolactin decreases progesterone levels by stimulating
hydroxysteroid dehydrogenase enzyme, which brings about
the catabolism of progesterone [52,64]. Similar observation
in birds is not clear but prolactin inhibits granulose cell proges-
terone at high doses [56] but not at lower, physiological doses
[17]. These support our ﬁndings that low levels of progesterone
as observed in ducks of the control group, which may also be
due to the catabolism of progesterone to 5a-dihydroprogester-
one or its epimer 5b-dihydroprogesterone. Marrone et al. [31]
and Reddy et al. [52], have been brought about by increased
peripheral prolactin concentration. On the other hand, estra-
diol in conjunction with progesterone primes the release of
LH [15]. The increase in oestradiol-17b levels after inhibiting
the high levels of prolactin suggests that prolactin levels may
be interfering with oestradiol synthesis [52]. Such observations
in birds are not clear, but it has been shown that prolactin can
inhibit only LH-stimulated oestradiol-17b production by
chicken follicles of <1 mm diameter [71]. High prolactin levels
may either interfere with the synthesis of androgens or FSH-
induced aromatase activity, leading to oestradiol-17b forma-
tion [52,53]. It is presumed that among the treated birds, the
increase in oestradiol could have been due to decreased prolac-
tin concentration. Since high levels of prolactin may inhibit
ovarian follicular steroidogenesis, not only does this interfere
with aromatase but it also reduces the production of androgen
precursor necessary for oestradiol-17b production by the theca
cells [34] and androstenedione is thecal in origin and its release
is stimulated by LH. It is possible that decreased prolactin lev-
els are attributed to increase in oestradiol and progesterone
levels, which may act as a positive feedback on secretion of
LH and subsequent ovulation [13,52]. It was found that the
higher egg production was associated with positively corre-
lated responses of high concentrations of LH, E2, and P4 re-
quired for completion of egg formation [52]. It is observed
from the above mentioned results that decreasing the prolactin
levels with GnRH treatment resulted in an increase in egg pro-
duction which could be achieved by abolishing the negative ef-
fect of prolactin on gonadotrophins steroidogenesis in the
gonads, activating the gonadotrophin receptors on the gonads,
increasing the levels of oestradiol and progesterone concentra-
tions, which in turn feed back on the anterior pituitary for elic-
98 K.M.A. Zoheir, R.G. Ahmediting the LH surge for ovulation and oviposition and increased
egg production with a decrease in intersequence pause days.
5. Conclusion
The results suggest that LHRH-A2 is involved in the regula-
tion of follicular development and increase egg production in
ducks. Also, the results demonstrate that LHRH-A2 may play
an important gonadotrope function during the folliculogenesis
process in ducks. Interestingly, a dose of 10 or 15 lg LHRH-
A2 mixed with feed/bird/day may be the optimal dosage. Fur-
ther studies on optimization of the GnRH dosage, schedule,
and possible secondary consequences of the presence of GnRH
in the egg yolk are needed. Furthermore, such an approach
and procedure could be extended to other species of economic
importance such as chicken, geese, and quails.Acknowledgments
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